Caring Ambassadors Hepatitis C Program Newsletter

September 2009


Clinical Trials, Cohort Studies, Pilot Studies


Validation of three non-invasive markers in assessing the severity of liver fibrosis in chronic hepatitis C. Shaikh S, Memon MS, Ghani H, et al. J Coll Physicians Surg Pak. 2009 Aug;19(8):478-82


Ethnicity and body mass Iindex are associated with hepatitis C presentation and progression. Kallwitz ER, Layden-Almer J, Dhamija M, et al. Clin Gastroenterol Hepatol. 2009 Aug 14. [Epub ahead of print]


Focal distribution of hepatitis C virus RNA in infected livers. Stiffler JD, Nguyen M, Sohn JA, Liu C, Kaplan D, Seeger C. 36: PLoS One. 2009 Aug 18;4(8):e6661.


Laparoscopic splenectomy with peginterferon and ribavirin therapy for patients with hepatitis C virus cirrhosis and hypersplenism. Akahoshi T, Tomikawa M, Korenaga D, et al. Surg Endosc. 2009 Aug 19. [Epub ahead of print]


Factors influencing long-term changes of mental health after interferon-alpha treatment of chronic hepatitis C. Schmidt F, Janssen G, Martin G, et al. Aliment Pharmacol Ther. 2009 Aug 18. [Epub ahead of print]


Efficacy and tolerability of rituximab with or without PEGylated interferon alfa-2b plus ribavirin in severe hepatitis C virus-related vasculitis: A long-term followup study of thirty-two patients. Terrier B, Saadoun D, Sène D, et al. Arthritis Rheum. 2009 Aug;60(8):2531-40.


Leukocyte interferon-alpha and ribavirin for treatment of chronic hepatitis C patients intolerant to pegylated-interferon. Adinolfi LE, Durante-Mangoni E, Salzillo M, et al. Intern Emerg Med. 2009 Aug 1. [Epub ahead of print]

Basic and Applied Science, Pre-Clinical Studies


Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance

Dongliang Ge1, Jacques Fellay1, Alexander J. et al. Nature advance online publication 16 August 2009


Endotoxin receptor CD14 gene variants and histological features in chronic HCV infection.

Askar E, Ramadori G, Mihm S.  World J Gastroenterol. 2009 Aug 21;15(31):3884-90.


Modulations of cell cycle checkpoints in HCV associated disease. Sarfraz S, Hamid S, Ali S, Jafri W, Siddiqui A. BMC Infect Dis. 2009 Aug 10;9(1):125


Hepatic inflammation mediated by hepatitis C virus core protein is ameliorated by blocking complement activation. Chang ML, Yeh CT, Lin DY, Ho YP, Hsu CM, Bissell DM. BMC Med Genomics. 2009 Aug 8;2(1):51. [Epub ahead of print]


Genetic variation in CLDN1 and susceptibility to hepatitis C virus infection. Bekker V, Chanock SJ, Yeager M, et al. J Viral Hepat. 2009 Aug 7. [Epub ahead of print]


HIV/HCV Coinfection


Treat early or wait and monitor? A qualitative analysis of provider hepatitis C virus treatment decision-making in the context of HIV coinfection. Wagner G, Ryan G, Osilla KC, Bhatti L, Goetz M, Witt M. AIDS Patient Care STDS. 2009 Aug 10. [Epub ahead of print]


Management of hepatitis C virus infection in HIV/HCV co-infected patients: clinical review. Singal AK, Anand BS. World J Gastroenterol. 2009 Aug 14;15(30):3713-24.


Determination of hepatitis C virus-infected, monocyte lineage reservoirs in individuals with or without HIV coinfection. Coquillard G, Patterson BK. J Infect Dis. 2009 Sep 15;200(6):947-54.



Occult hepatitis B virus infection in a cohort of HIV-positive patients: Correlation with hepatitis C virus coinfection, virological and immunological features. Morsica G, Ancarani F, Bagaglio S, et al. Infection. 2009 Aug 7. [Epub ahead of print]


Longitudinal evaluation of viral interactions in treated HIV-hepatitis B co-infected patients with additional hepatitis C and D virus. Boyd A, Lacombe K, Miailhes P, et al. J Viral Hepat. 2009 Aug 4. [Epub ahead of print]


Diagnosis of advanced fibrosis in HIV and hepatitis C virus-coinfected patients via a new noninvasive index: the HGM-3 index. Resino S, Micheloud D, Miralles P,et al. HIV Med. 2009 Aug 3. [Epub ahead of print]


Epidemiology, Diagnostics, and Miscellaneous Works


Quality of life considerations for patients with chronic hepatitis C. Foster GR. J Viral Hepat. 2009 Sep;16(9):605-11. Epub 2009 Aug 5.


Risk behaviors after hepatitis C virus seroconversion in young injection drug users in San Francisco. Tsui JI, Vittinghoff E, Hahn JA, Evans JL, Davidson PJ, Page K. Drug Alcohol Depend. 2009 Jul 30. [Epub ahead of print]


The evolution of the major hepatitis C genotypes correlates with clinical response to interferon therapy. Pang PS, Planet PJ, Glenn JS. PLoS One. 2009 Aug 11;4(8):e6579.


Assessment and proposal of a new combination of screening criteria for hepatitis C in France. King LA, Le Strat Y, Meffre C, Delarocque-Astagneau E, Desenclos JC. Eur J Public Health. 2009 Aug 10. [Epub ahead of print]


Ultrasound surveillance for early detection of hepatocellular carcinoma among patients with chronic hepatitis C. Sato T, Tateishi R, Yoshida H, et al. Hepatol Int. 2009 Aug 6. [Epub ahead of print]

A methodology for successfully producing global translations of patient reported outcome measures for use in multiple Countries.  Two R, Verjee-Lorenz A, Clayson D, et al. Value Health. 2009 Aug 20. [Epub ahead of print]


Prevalence of hepatitis C infection in New York City, 2004. Bornschlegel K, Berger M, Garg RK, et al. J Urban Health. 2009 Aug 12. [Epub ahead of print]